Chimeric antigen receptor (CAR) T-cell therapies are the newest drug class in the continued development of personalized oncology treatments. The introduction of CAR T-cell therapy to aggressive hematological malignancies is transforming the treatment landscape for patients with relapsed/refractory disease, previously thought to be incurable.

Despite only just reaching the commercial market, development in this area is advancing at an unprecedented speed. Researchers are working to expand their utility into more indications, with solid tumors firmly on the radar.

In this eBook, DRG Oncology expert Amy Yip shares her perspective on emerging therapies and trends shaping the future of the CAR T-cell therapy landscape.

Key topics covered include:

  • Current leading therapies
  • Emerging players, agents and trials to watch
  • Disease management and access issues
  • Perspectives from oncologist KOLs
  • Takeaways for biopharma strategists




DRG becomes Clarivate

View Now